LY4064912 + LY4064912 + Placebo + Placebo

Phase 1Recruiting

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Overweight or Obesity

Conditions

Overweight or Obesity, Healthy

Trial Timeline

Aug 28, 2025 → Nov 1, 2026

NCT ID

NCT07152002

About LY4064912 + LY4064912 + Placebo + Placebo

LY4064912 + LY4064912 + Placebo + Placebo is a phase 1 stage product being developed by Eli Lilly for Overweight or Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07152002. Target conditions include Overweight or Obesity, Healthy.

What happened to similar drugs?

1 of 20 similar drugs in Overweight or Obesity were approved

Approved (1) Terminated (0) Active (19)

✅AripiprazoleBristol Myers SquibbApproved

🔄Eloralintide + PlaceboEli LillyPhase 3

🔄Tirzepatide + PlaceboEli LillyPhase 3

🔄Maridebart cafraglutide + PlaceboAmgenPhase 3

🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07152002	Phase 1	Recruiting	Aug 28, 2025	Nov 1, 2026	Overweight or Obesity

Competing Products

20 competing products in Overweight or Obesity

See all competitors

Product	Company	Stage	Hype Score
TERN-601	Terns Pharmaceuticals	Phase 2	32
LY3457263 + Tirzepatide + Placebo	Eli Lilly	Phase 1	29
LY3305677 + Placebo	Eli Lilly	Phase 1	29
LY3537031 + Placebo	Eli Lilly	Phase 1	33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)	Eli Lilly	Phase 2	42
Eloralintide + Placebo	Eli Lilly	Phase 3	47
LY3437943 + Ethinyl Estradiol + Drospirenone	Eli Lilly	Phase 1	29
Tirzepatide + Acetaminophen	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 2	39
Eloralintide + Placebo	Eli Lilly	Phase 3	47
LY3437943 + Placebo	Eli Lilly	Phase 1	29
LY3502970 + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	44
Eloralintide and Tirzepatide + Eloralintide	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
LY3541105 + Placebo	Eli Lilly	Phase 1	29
Retatrutide + Placebo	Eli Lilly	Phase 2	35
LY4167586 + Placebo + LY4167586	Eli Lilly	Phase 1	36
AZD9550 + AZD6234 + Placebo comparator	AstraZeneca	Phase 2	39
pramlintide acetate + sibutramine + phentermine + placebo	AstraZeneca	Phase 2	35